$AB

AllianceBernstein: Q2 Earnings Snapshot

AllianceBernstein Holding LP (AB) reported Q2 net income of $71.7 million, or 77 cents per share. Adjusted earnings were 82 cents per share. Revenue was $1.17 billion, with adjusted revenue of $887.5 million. The article notes AB shares down 1.5% YTD and 12% over 12 months.

Original reporting
Published Jul 28, 2026, 9:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 28, 2026, 9:38 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$AB
Neutral
medium confidence
Mentioned
$AB
Relevance
6/10
alphai data visualization · based on local3news.com
Decision brief

The 30-second read

$ABNeutralMed
01

Why it matters

Traders can use the reported net income, EPS, and revenue figures to benchmark against expectations, but the article does not provide guidance or estimate context.

02

Market read

Earnings print may influence AB’s near-term valuation, but the lack of consensus and forward outlook reduces decision quality.

03

What to watch

Key items for asset managers are missing here, such as AUM, net flows, fee rate changes, and expense trends, which often explain earnings-driven moves.

Relevance 6/10Novelty 6/10Timing: after-hours earnings snapshot for Q2

Background

The piece is an AP-generated earnings snapshot for AllianceBernstein’s second quarter.

Company-level read

Ticker impact

$ABNeutralMedium confidence
Context

AllianceBernstein reported Q2 net income of $71.7 million, or 77 cents per share, and adjusted EPS of 82 cents.

Expected impact

Likely modest volatility around the earnings print, but direction is unclear without consensus or guidance.

Evidence & confidence

It includes hard financial figures but no guidance, margin detail, or analyst estimate comparison, limiting conviction on whether the print is a beat or miss.

Market effects

Adds another datapoint for the asset management earnings tape, but no sector-wide conclusions are drawn.

No specific regional demand or policy linkage is provided beyond the company’s Nashville base.

No international flows, macro drivers, or cross-border regulatory impacts are mentioned.

Counterpoint

Without consensus estimates, the earnings numbers alone may not justify a directional trade; price reaction could be driven by what was not reported (guidance, AUM, fees).

Key entities

  • AllianceBernstein Holding LP

    Reported Q2 net income of $71.7 million, EPS of 77 cents (82 cents adjusted), and revenue of $1.17 billion (adjusted $887.5 million).

Related articles

$ABMedAI 8/10

AB Science raises EUR 14.2m to fund masitinib Phase III, AB8939

AB Science (Euronext Paris: AB) raised EUR 14.2m via a private placement to fund early steps of a strategic plan due in September. The issue created 23.28m new shares; an existing long-term investor provided EUR 12m. Proceeds target AB8939 in AML and masitinib Phase III in ALS. Cash is about EUR 23m, covering needs beyond 12 months.

$ABMed

AllianceBernstein Holding L.P. Q2 2026 Earnings Call Summary

Strategic Execution and Platform Scaling Achieved record AUM of $905 billion, driven by a return to positive organic growth and the strongest gross sales quarter in five years. Reached the $90 billion to $100 billion private markets AUM target more than a year ahead of schedule, validating a multi-year investment strategy in corporate lending and real estate debt.

$ABMed

AllianceBernstein Holding LP (AB) Q2 2026 Earnings Call Highlights: Record AUM

AllianceBernstein (AB) discussed Q2 2026 earnings call topics, including expectations for the Equitable Corebridge merger to add about $100B of AUM over a couple of years, with combined general account assets around $350B and separate around $200B. Management cited resilient private wealth adviser productivity, reduced expense guidance by $5-10M, and demand shifts in U.S. taxable fixed income.

$ABMedAI 8/10

Advanced Bionics Receives FDA Approval for Expanded Cochlear Implant Candidacy Criteria in SSD and AHL

Advanced Bionics, a Sonova brand, said the US FDA approved expanded indications for its cochlear implant systems for single-sided deafness (SSD) and asymmetric hearing loss (AHL). The criteria broaden adult and pediatric eligibility, with company-cited research estimating 271,000 to 345,000 US adults with SSD and only 2.1% using CIs among eligible patients.

$ABMed

ALLIANCEBERNSTEIN HOLDING L.P. (AB): Results of Operations and Financial Condition

ALLIANCEBERNSTEIN HOLDING L.P. (AB) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.01 2 a2q26earningsrelease.htm EX-99.01 2Q26 RELEASE Document Ioanis Jorgali, Investors 629.213.6139 ioanis.jorgali@alliancebernstein.com Carly Symington, Media 629.213.5568 carly.symington@alliancebernstein.com ALLIANCEBERNSTEIN HOLDING L.P. ANNOUNCES SECOND QUARTER RESULTS

$GCOMed

102-year-old mall retailer quietly closes 25 stores

Genesco (GCO) closed 25 stores, including 17 Journeys locations, in Q2 fiscal 2027, per its earnings release. Net sales fell 3% YoY to $530M, with comparable sales down 1%. The company is shifting away from malls and remodeling stores to boost sales, with 4.0 Journeys stores showing 25% higher sales.